Key result
Flecainide acetate administration in dogs with recent myocardial infarction increased the incidence of ventricular fibrillation during acute ischemia compared to saline.
Why the study?
Does flecainide acetate prevent ventricular tachyarrhythmia and fibrillation in dogs with recent myocardial infarction?
Does flecainide acetate prevent ventricular tachyarrhythmia and fibrillation in dogs with recent myocardial infarction?
In a post-myocardial infarction dog model, flecainide acetate failed to prevent ventricular tachycardia and demonstrated proarrhythmic effects by increasing the risk of ventricular fibrillation during acute ischemia.
Answers are grounded in this paper and cite their sources.
Flecainide increases VF risk during post-MI ischemia; challenges antiarrhythmic benefit and leaves open human translation.
The antiarrhythmic and antifibrillatory actions of the class IC antiarrhythmic agent flecainide acetate were examined in urethane-anesthetized dogs with recent myocardial infarction. The intravenous administration of flecainide in a loading dose of 1.0 mg/kg (n = 7) or 2.0 mg/kg (n = 6), followed by a maintenance infusion of 1.0 mg/kg/h to achieve plasma drug concentrations considered clinically therapeutic, failed to significantly elevate the electrical threshold current required to provoke ventricular fibrillation at infarct zone, border zone and non-infarct zone stimulation sites in postinfarction dogs. In 8 dogs which responded to baseline programmed stimulation with inducible sustained ventricular tachycardia, flecainide administered as 1.0 or 2.0 mg/kg loading doses followed by a 1.0 mg/kg/h maintenance infusion failed to prevent ventricular tachycardia initiation in any animal tested, although the post-treatment ventricular tachycardia cycle lengths were prolonged compared to baseline values (pre: 178 +/- 11 ms vs post: 202 +/- 17 ms, p less than 0.05). Flecainide administration apparently facilitated the induction of newly sustained ventricular tachycardia in 3 previously noninducible postinfarction dogs. The development of acute posterolateral ischemia at a site remote from previous anterior myocardial infarction resulted in the development of ventricular fibrillation in 4 of 11 (36%) saline-treated postinfarction dogs vs a cumulative 10 of 12 (83%) flecainide-treated, baseline noninducible postinfarction dogs (p less than 0.05 vs saline-treated). The incidence of sudden ischemic ventricular fibrillation was 7 of 7 (100%) among flecainide-treated baseline inducible postinfarction dogs. These data suggest that flecainide acetate may have only limited efficacy in preventing ventricular tachycardia or ventricular fibrillation soon after myocardial infarction.
No takes yet. Share an insight, caveat, or question.
Lynch et al. (2008) studied Recent myocardial infarction. Flecainide acetate vs. Saline was evaluated on Development of ventricular fibrillation during acute posterolateral ischemia (p=<0.05). Flecainide acetate administration in dogs with recent myocardial infarction increased the incidence of ventricular fibrillation during acute ischemia compared to saline.
Synapse has enriched 10 related papers. Consider them for comparative context: